211 related articles for article (PubMed ID: 31481510)
21. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
22. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
Liu SY; Eary JF; Petersdorf SH; Martin PJ; Maloney DG; Appelbaum FR; Matthews DC; Bush SA; Durack LD; Fisher DR; Gooley TA; Bernstein ID; Press OW
J Clin Oncol; 1998 Oct; 16(10):3270-8. PubMed ID: 9779701
[TBL] [Abstract][Full Text] [Related]
23. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.
Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR; Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M; Cottler-Fox M; Chen T; Phillips G; Tricot G
Bone Marrow Transplant; 2002 Feb; 29(4):303-12. PubMed ID: 11896427
[TBL] [Abstract][Full Text] [Related]
24. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
26. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
27. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
[TBL] [Abstract][Full Text] [Related]
28. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
[TBL] [Abstract][Full Text] [Related]
29. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma.
Vaklavas C; Meredith RF; Shen S; Knox SJ; Micallef IN; Shah JJ; LoBuglio AF; Forero-Torres A
Cancer Biother Radiopharm; 2013 Jun; 28(5):370-9. PubMed ID: 23530878
[TBL] [Abstract][Full Text] [Related]
31. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD
Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
[TBL] [Abstract][Full Text] [Related]
32. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
Gopal AK; Gooley TA; Rajendran JG; Pagel JM; Fisher DR; Maloney DG; Appelbaum FR; Cassaday RD; Shields A; Press OW
Biol Blood Marrow Transplant; 2014 Jun; 20(6):770-5. PubMed ID: 24530971
[TBL] [Abstract][Full Text] [Related]
33. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
34. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
[TBL] [Abstract][Full Text] [Related]
35. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
36. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
37. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study.
Stathis A; Flinn IW; Madan S; Maddocks K; Freedman A; Weitman S; Zucca E; Munteanu MC; Lia Palomba M
Invest New Drugs; 2018 Oct; 36(5):869-876. PubMed ID: 29453628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
